Synavive (prednisolone/dipyridamole) / Sun Pharma - LARVOL DELTA

Halozyme Therapeutics and Zalicus recent movers in a booming industry (Marketwire) - Zalicus stocks were up by 12% on Tuesday Aug 7, 2012

Stock price • Pain

4 reasons to buy Zalicus (SeekingAlpha) - Anticipated Synavive P2b results in Sep 2012; Synavive's estimated market potential $2B to $4B

Anticipated P2b data • Sales projection • Rheumatoid Arthritis

Zalicus reports financial results for the fourth quarter and year end 2011 (Businesswire) - Completion of P2b SYNERGY rheumatoid arthritis clinical trial and top-line data expected in the Q3 2012

Anticipated P2b data • Anticipated P2b trial completion • Pain

Zalicus initiates phase 2b clinical trial of Synavive in rheumatoid arthritis (Businesswire) - Zalicus announced initiation of P2b SYNERGY trial; Top line results of clinical trial are expected to be available in the H2 '12; Zalicus has drawn an additional $8.5M from its $20M secured credit facility with Oxford Finance to fund Synavive advancement

Anticipated P2b data • Pain • Rheumatoid Arthritis